- Conditions
- Treatment-resistant Depression (TRD)
- Interventions
- ALTO-207, Placebo
- Drug
- Lead sponsor
- Alto Neuroscience
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 53
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Chino, California + 49 more
Clinical trials in Baltimore, Maryland
This page shows live ClinicalTrials.gov search results for Baltimore, Maryland, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Baltimore
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Congenital Diaphragmatic Hernia
- Interventions
- 11540KE and Balt Goldbal 2 balloon
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer
- Interventions
- HER3-DXd
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 14
- States / cities
- Duarte, California • New Haven, Connecticut • Kissimmee, Florida + 11 more
- Conditions
- Overweight and Obesity
- Interventions
- WVE-007
- Drug
- Lead sponsor
- Wave Life Sciences USA, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Baltimore, Maryland
- Conditions
- Autoimmune Pulmonary Alveolar Proteinosis
- Interventions
- Molgramostim nebulizer solution
- Drug
- Lead sponsor
- Savara Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Gainesville, Florida • Baltimore, Maryland + 9 more
- Conditions
- Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
- Interventions
- cytotoxic t-lymphocytes
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 1 Month to 79 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- AZD6793, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 987 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more
- Conditions
- Hypertension
- Interventions
- Saline, QCZ484
- Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 63
- States / cities
- Andalusia, Alabama • Huntsville, Alabama • Saraland, Alabama + 58 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Elafibranor 80 mg, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg, Placebo Matched to Elafibranor 120 mg
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 30
- States / cities
- Lancaster, California • Los Angeles, California • Sacramento, California + 26 more
- Conditions
- Tenofovir
- Interventions
- Oral F/TDF Pills, TFV rectal douche
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Lawrenceville, Georgia + 5 more
- Conditions
- Advanced Renal Cell Carcinoma (RCC)
- Interventions
- Pumitamig, Ipilimumab, Cabozantinib, Casdatifan
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 17
- States / cities
- Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
- Conditions
- Breast Cancer
- Interventions
- anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 1454
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 888 more